Bringing medical advances from the lab to the clinic.
![]()
（点击👆，免费获取美国NIH基金资助项目大数据分析）
双相情感障碍（Bipolar Disorder），又称为躁郁症，是一种严重的心理健康状况，特征是患者的情绪状态在极端的高涨（躁狂期）和严重的抑郁（抑郁期）之间波动。这种情绪波动远超常人经历的正常情绪变化，且可以极大地影响患者的日常生活和功能。
尽管近年来在双相情感障碍的诊断和治疗方面取得了显著进展，但仍存在一些重要而未解决的临床问题：- 诊断挑战：双相情感障碍的诊断通常较为复杂，特别是与其他心理健康状况（如单相抑郁症、焦虑症、边缘性人格障碍）的鉴别。早期诊断尤为困难，因为躁狂期的症状可能被误解为个性特质或单独的行为问题。
- 治疗选择：虽然有多种药物（如情绪稳定剂、抗抑郁药和抗精神病药）和心理治疗可用于治疗双相情感障碍，但个体对治疗的反应差异很大，且常需长期治疗。找到合适的药物组合和剂量常需要时间并可能需要经常调整。
- 复发管理：即便在接受治疗的情况下，许多患者也会经历情绪稳定后的复发。如何有效预防和管理复发是一个重要的临床问题。
- 长期健康问题：双相情感障碍与多种长期健康问题相关，包括心血管疾病、代谢综合征和认知功能下降。这要求治疗方案不仅要考虑情感稳定，也需关注整体健康。
综上所述，双相情感障碍的治疗需要一个综合性的方法，包括药物治疗、心理治疗、生活方式的调整及可能的支持性治疗，以提高患者的生活质量和减少复发。对这些未解决问题的持续研究对于改善患者的长期治疗结果至关重要。
我们仅对美国国立卫生研究院（NIH）资助的在研双相情感障碍相关项目进行梳理，希望给同仁们的选题思路提供一点启发。
2024年，以“Bipolar Disorder”为检索词、在题目中进行检索，美国NIH针对双相情感障碍的在研有38项。- NATIONAL INSTITUTE OF MENTAL HEALTH 的 MCMAHON, FRANCIS J
- ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 的 ROUSSOS, PANAGIOTIS
- UNIVERSITY OF TEXAS AT AUSTIN 的 STRAKOWSKI, STEPHEN M
- MASSACHUSETTS GENERAL HOSPITAL 的 ELLARD, KRISTEN K
UNIVERSITY OF COLORADO 的 GRUBER, JUNE L
国家心理健康研究所
德克萨斯大学奥斯汀分校
密歇根大学安娜堡分校
匹兹堡大学匹兹堡分校
西奈山伊坎医学院等
![]()
双相情感障碍研究大的方向包括自杀行为（Suicidal Behavior）、双相情感障碍患者（BD Patients）、脑网络（Brain Network）、遗传学（Genetics）、年轻人（Young Adults）、基因表达（Gene Expression）等。我们也分享在双相情感障碍领域的几项课题摘要，希望对同仁们有所启发。A，Multiethnic genomic epigenomic and transcriptomic fine-mapping and functional validation analysis of schizophrenia and bipolar disorder risk lociThe overarching goal of our proposal is to leverage genomics and multiscale functional omics (gene expression and epigenome regulation) data and perform fine mapping to detect and validate causal variants, transcripts and regulatory sequences in SMI. In Aim 1, we will perform large-scale trans- ancestry GWAS of SCZ and BD to expand the current repertoire of risk (and resilience) loci and refine the credible sets of causal variants underlying genome-wide significant associations. In Aim 2, we will integrate putative causal variants with multiscale functional omics data from human brain tissue that capture gene expression and epigenome regulation at the bulk, cell type-specific and single cell level to identify credible sets of transcripts and regulatory sequences. In Aim 3, we will functionally validate putative causal variants and regulatory sequences, by using novel approaches that combine massively parallel reporter assays and genome editing in excitatory and inhibitory neurons derived from human induced pluripotent stem cells. Our computational and experimental aims bridge the gap between the fine-mapping of causal variants, the molecular gene- regulatory effects of risk variants on enhancer activity and gene expression and their biological effects at the cellular level. If successful, our project can elucidate the genes, pathways, and mechanisms underlying SCZ and BD, and provide new insights and avenues for therapeutic development.B, 1/2 Neurodevelopmental and clinical trajectories of youth at risk for bipolar I disorderWith these considerations in mind, we hypothesize that heritability for bipolar I disorder interacts with early life adversity to synergistically disrupt healthy ventral prefrontal network development during adolescence, underlying a cumulative increased risk for developing mania and other conditions more common in bipolar families. To test this hypothesis, over a four-year interval we will assess trajectories in ventral prefrontal network connectivity in youth at-familial-risk for bipolar I disorder compared to those without this risk, and the interaction with or without early life trauma, to determine whether these risks cumulatively lead to increasing emergence of: 1) mood symptoms and syndromes, 2) substance misuse, 3) suicidal behaviors, and 4) approach motivation hypersensitivity. These results can inform future approaches to prevent illness onset and progression in individuals at risk for or early in the course of bipolar disorder.如果您需要HS提供类似的选题大数据分析，可阅读下面的推文：应用这个“外挂”，他的选题思路源源不断、文章不断发表！
作者：Amber Wang；助理：ChatGPT；编辑：Jessica，微信号：Healsanq，加好友请注明理由。美国Healsan Consulting(恒祥咨询)，于2016年创建于美国首都大华府地区，专长于Healsan医学大数据分析（Healsan™）、及基于大数据的Hanson临床科研培训（HansonCR™）和医学编辑服务（MedEditing™）。主要为医生科学家、生物制药公司和医院科研处等提供分析和报告，成为诸多机构的“临床科研外挂”。点击👆；From Bench to Bedside, Healsan Paves the Path.▼ 支持基金申请和SCI论文发表，推动临床科研的创新与发展。基于Healsan™文献计量大数据的系列推文，全年安排如下；目前是美国基金解析系列。
